Sofinnova Partners grows crossover fund by 63% to €725m, eyes European life sciences funding gap
Monday, November 16, 2026 · first reported by AltAssets and 4 others
Sofinnova Partners has closed Sofinnova Crossover II at €725 million ($815 million per HedgeCo), above its original target. AltAssets puts the fund at 63% larger than its predecessor.
The vehicle will hold about 15 companies, mainly European clinical-stage biopharma and medtech businesses needing capital to reach commercialization, with some investments in the United States and elsewhere. Partner Kinam Hong said about 80% will go to Europe. Investing has begun, with Neurent Medical, Hemab Therapeutics and CellCentric among the first holdings.
- Size
- €725M (≈$789M)
- Stage
- Target
- Asset class
- Private equity, Venture
- Geography
- Europe
In the data This close in the fund closes table · Every Sofinnova close
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
Coverage
5 sources- AltAssetsSofinnova Partners grows crossover fund by 63% to €725m, eyes European life sciences funding gap
- Alternatives WatchSofinnova raises €725m for second crossover fund
- HedgeCoSofinnova Partners closed its Crossover II fund at €725 million, above target, to back Late-Stage European Life Sciences companies
- STT InfoSofinnova Partners Closes €725M Crossover II Fund
- Via TTSofinnova Partners Closes €725M Crossover II Fund
- Blackstone eyes $8bn for third core private equity fundPrivate Equity News
- Blue Sea Capital closed its first Healthcare-Only fund at $800 million, above its hard capHedgeCo
- Aphias Capital closes oversubscribed debut fund at $1.05BDealroom
- CVC seeks to exit near-€3bn Irca deal with AdventPrivate Equity Wire
- Horizon Capital reached €200 million at the second close of its Ukraine-Focused Catalyst fundHedgeCo
- Japan's Polaris Capital to launch $300 million fund for late-stage startupsnews.lavx.hu +1
Got news? Send it to us →